• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Lenvatinib plus pembrolizumab improves overall survival and progression free survival for advanced renal cell carcinoma treatment

byConstance Wu
April 20, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Lenvatinib plus pembrolizumab was superior to sunitinib in overall survival for patients with advanced renal cell carcinoma.

2. Lenvatinib plus pembrolizumab demonstrated longer progression-free survival compared to sunitinib.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The standard treatment of advanced renal cell carcinoma (RCC) has been antagonism of vascular endothelial growth factor (VEGF) with tyrosine kinase inhibitors such as sunitinib. Lenvatinib, an antiangiogenic agent, and pembrolizumab, an anti-programmed cell death 1 monoclonal antibody, have been explored in previous studies as monotherapies for RCC. As such, this study reported the efficacy and safety of lenvatinib plus pembrolizumab treatment compared to sunitinib in patients with advanced RCC. The study determined pembrolizumab plus lenvatinib treated patients had superior progression-free survival and overall survival compared to sunitinib. The most common adverse event was diarrhea, which was greater in the combination therapy group. There was more drug discontinuation in the lenvatinib and pembrolizumab group compared to the lenvatinib and everolimus group or the sunitinib group. One limitation is that patients and investigators were aware of the treatment assignments. Overall, this trial demonstrated that lenvatinib and immune-checkpoint inhibition with pembrolizumab showed superior survival compared to sunitinib alone.

Click here to read the study in the NEJM

Relevant Reading: Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma

In-Depth [randomized controlled trial]: This was a multicenter, randomized, open-label trial of 1,069 patients from 200 sites in 20 countries. Patients 18 years of age or older with advanced renal carcinoma, and no prior systemic therapy were included in the study. Patients were excluded from the study if there was not adequate blood pressures control or organ function. Patients were randomized in a 1:1:1 ratio into lenvatinib and pembrolizumab, lenvatinib and everolimus, or sunitinib, respectively. Everolimus and lenvatinib treatment (median, 14.7 months) had significantly longer progression-free survival compared to sunitinib (median, 9.2 months) (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.53 to 0.80; P < 0.001). However, the overall survival between both groups was not significant (HR, 1.15; 95% CI, 0.88 to 1.50; P = 0.30). Pembrolizumab and lenvatinib was superior in both progression-free survival (treatment median, 23.9 months; control median, 9.2 months; HR, 0.39; 95% CI, 0.32 to 0.49; P < 0.001) and overall survival (HR, 0.66; 95% CI, 0.49 to 0.88; P = 0.005) when compared to sunitinib. Grade 3 or higher adverse events was observed in 82.4% of the lenvatinib plus pembrolizumab group, 83.1% of the lenvatinib plus everolimus group, and 71.8% of the patients who received sunitinib. In general, this trial demonstrated the use of an immune checkpoint inhibitor is an important treatment component for advanced RCC in combination with standard VEGF inhibition.

RELATED REPORTS

Plant-based diets may be associated with lower risk of aggressive prostate cancer

Spiritual care reduces fatigue and pain among patients receiving chemotherapy

Religious-based interventions improve illness perception in breast cancer patients

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cancerkidneylenvatinibpdl-1PembrolizumabRCCrenalrenal cell neoplasmrenal-cell carcinomaVEGF
Previous Post

Comparative efficacy of psychotherapies for reducing self-harm and suicidality in young individuals shows inconsistent and low-quality evidence

Next Post

Use of bamlanivimab for patients with mild to moderate COVID-19 infection

RelatedReports

Vegetarian diet may lower incidence of colorectal cancer
Lifestyle

Plant-based diets may be associated with lower risk of aggressive prostate cancer

January 27, 2023
No benefit of erlotinib in combined hepatocellular carcinoma treatment
Oncology

Spiritual care reduces fatigue and pain among patients receiving chemotherapy

January 11, 2023
Palliative care consultation linked to lower deaths by failed code resuscitation
Oncology

Religious-based interventions improve illness perception in breast cancer patients

January 9, 2023
#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer
StudyGraphics

#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

January 4, 2023
Next Post
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

Use of bamlanivimab for patients with mild to moderate COVID-19 infection

Radiation plus chemotherapy confers survival benefit compared to radiation alone in low-grade gliomas

Immunovirotherapy showed acceptable adverse-event profile in pediatric high-grade gliomas

Parents often unaware of adolescents’ suicidal thoughts

Psilocybin does not significantly improve depressive scores compared to escitalopram

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis
  • Gender-affirming hormones improve psychosocial functioning in transgender youth
  • Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options